Navigation Links
Statement by Ronald L. Stotish, Ph.D., President and CEO of AquaBounty Technologies
Date:6/16/2011

WALTHAM, Mass., June 16, 2011 /PRNewswire-USNewswire/ -- Background: The U.S. House of Representatives yesterday passed an amendment to H.R. 2112, the House agricultural appropriations bill, co-sponsored by Rep. Don Young (R-AK) and Rep. Lynn Woolsey (D-CA) to prohibit funding for U.S. Food and Drug Administration approval of salmon grown from AquaBounty Technologie's AquAdvantage salmon eggs.  The amendment was voted on by fewer than ten of the total 435 House members.

The U.S. FDA has conducted a rigorous 15-year review of thousands of pages of data and has concluded that these fish are exactly the same as any other Atlantic salmon and, therefore, are safe for consumption.  In addition, the fish will be sterile and required to be grown in self-contained inland tanks, so pose no threat to the environment.  Finally, the United Nations reports that the wild caught fisheries are severely stressed, with  major food species potentially extinct by 2050, yet the demand for fish protein is exploding worldwide. America currently imports more than 97% of the Atlantic salmon consumed here, so Young et al are really supporting foreign salmon producers.

Statement:

"This outrageous action is wrong on the facts, wrong on the process and wrong on the policy.  A handful of representatives have chosen to subvert the FDA's rigorous 15-year plus process. It completely ignores the results of a rigorous scientific review. This sort of political gamesmanship undermines the science-based system that protects the nation's health and safety. It is astonishing that Young and a few colleagues would try to game the system in this way."

"Whether or not you support this transgenic salmon, we should all agree these types of shenanigans have no place in a complex scientific debate.  These actions threaten the fundamental basis of a science-based regulatory process. Americans deserve better from their elected representatives."


'/>"/>
SOURCE AquaBounty Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Issues a Management Statement
2. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Sinovac Releases Statement on Healive Vaccine Suspension
5. CV Therapeutics Statement on Unsolicited Proposal From Astellas
6. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
7. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
8. Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
9. Advanced Life Sciences Announces Filing of Shelf Registration Statement
10. Amylin Issues Statement in Response to Carl Icahn
11. DuPont Statement on Obama Administration Biofuels Interagency Working Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... NEW YORK , February 4, 2016 ... (OTCQB: QBIO), a biotechnology acceleration company is pleased to provide ... --> --> Over the last 3 months ... note and securities purchase agreements exceeding $1,000,000. As a result, ... under our Mannin Research Inc. license agreement and expect that ...
(Date:2/4/2016)... England , February 4, 2016 ... Bioscience Laboratories (ABL), Inc. --> Strasbourg, France ... Inc. --> PharmaVentures is pleased to announce that ... of its biopharmaceutical manufacturing unit in Strasbourg, France ... Inc. --> --> Transgene ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
Breaking Biology News(10 mins):